#1221601
AbbVie US LLC #0074106501

SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1.2 mL

Name: Monoclonal Antibody
Brand: SKYRIZI®

SKYRIZI, INJ 180MG/1.2ML PF CARTRIDGE W/OBI D/S

SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1.2 mL

Compare

Product Specifications

McKesson #

1221601

Manufacturer #

0074106501

Brand

SKYRIZI®

Manufacturer

AbbVie US LLC

Country of Origin

Germany

Application

Monoclonal Antibody

Container Type

Single-Dose Prefilled Cartridge

Dosage Form

Injection

Generic Drug Code

53397

Generic Drug Name

Risankizumab-rzaa

NDC Number

00074106501

Product Dating

McKesson Acceptable Dating: we will ship >= 180 days

Storage Requirements

Requires Refrigeration

Strength

150 mg / mL

Type

Subcutaneous

UNSPSC Code

51241200

Volume

1.2 mL

Features

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
180 mg/1.2 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector

Professionals Also Viewed

View Full Comparison

#1242449
Novartis #00078116861

COSENTYX® Secukinumab 25 mg / mL Injection 5 mL

Carton containing one 125 mg / 5 mL (25 mg / mL) solution in a single- …

#1194022
AbbVie Inc #00074210001

SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1 mL

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
Single-Dose Pen

#1194021
AbbVie Inc #00074105001

SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection 1 mL

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
Single-Dose Prefilled Syringe

#1212567
AbbVie US LLC #00074501501

SKYRIZI® Risankizumab-rzaa 60 mg / mL Injection 10 mL

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque p …
SKYRIZI is indicated for the treatment of active psoriatic arthritis i …
SKYRIZI is indicated for the treatment of moderately to severely activ …